Publications & Reports

No difference in the rate of change in telomere length or telomerase activity in HIV-infected patients after three years of Darunavir/Ritonavir with and without nucleoside analogues in the MONET trial.

Solomon A, Tennakoon S, Leeansyah E, Arribas J, Hill A, Van Delft Y, Moecklinghoff C, Lewin SR
Department of Infectious Diseases, Monash University and Alfred Health, Centre for Biomedical Research, Burnet Institute, Melbourne, Australia.

Abstract

OBJECTIVE: To determine whether nucleos(t)ide reverse transcriptase inhibitors (NRTI) contribute to an accelerated loss in telomere length (TL) in HIV-infected patients on antiretroviral therapy (ART). DESIGN: Substudy of randomised controlled trial. METHODS: Patients with HIV RNA <50 copies/mL on combination ART (n = 256) were randomised to darunavir/ritonavir (DRV/r) 800/100 mg once daily, either as monotherapy (n = 127) or with 2 NRTIs (n = 129) for up to 144 weeks. TL and telomerase activity was quantified on stored peripheral blood mononuclear cells (PBMC; n = 124) using quantitative real time PCR. RESULTS: Patients in the sub-study had a mean age of 44 years and had received NRTI for a mean of 6.4 years (range 1-20 years). As expected, older patients have significantly shorter TL (p = 0.006), while women had significantly longer TL (p = 0.026). There was no significant association between TL and either the duration of prior NRTI treatment (p = 0.894) or the use of a PI versus NNRTI (p = 0.107). There was no significant difference between patients who continued or ceased NRTI in the mean change/year of TL or telomerase (p = 0.580 and 0.280 respectively). CONCLUSION: Continuation versus cessation of NRTI treatment was not associated with an accelerated loss in TL or telomerase activity.

Publication

  • Journal: PloS One
  • Published: 04/11/2014
  • Volume: 9
  • Issue: 11
  • Pagination: e109718

Health Issue

Download